Asciminib

Description

Asciminib · CAS 2119669-71-3 · C20H19Cl2F2N5O3. UNII C5U34S9XFV.

Identification

Computed Descriptors

Documented Uses

• Asciminib hydrochloride is approved to treat adults with:
• • chronic myelogenous leukemia (CML) that is in chronic phase and is Philadelphia chromosomepositive. It is used:
• • in patients who have received at least two tyrosine kinase inhibitors
• • in patients whose CML has the T315I mutation
• • in patients with newly diagnosed CML¹
• ¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that asciminib hydrochloride provides a clinical benefit in these patients.Asciminib hydrochloride is also being studied in the treatment of other types of cancer.

Synonyms

Asciminib hydrochloride; 2119669-71-3; ABL001-AAA; C5U34S9XFV; RefChem:58303; Asciminib (hydrochloride); Scemblix; Asciminib hydrochloride [USAN]; UNII-C5U34S9XFV; Asciminib HCl; Scemblix (TN); Asciminib hydrochloride [MI]; orb1686815; orb1940871; CHEMBL4297220; SCHEMBL22656445

Frequently Asked Questions

What are the CAS number and molecular formula of Asciminib?

CAS 2119669-71-3; molecular formula C20H19Cl2F2N5O3; molecular weight — g/mol.

What other names is Asciminib known by?

Asciminib hydrochloride, 2119669-71-3, ABL001-AAA, C5U34S9XFV, RefChem:58303, Asciminib (hydrochloride).

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.